v3.26.1
Consolidated Statements of Stockholders' Deficit - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Stock Subscription Receivable [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2023 $ 1,764 $ 9,701,774 $ (11,109,195) $ (1,405,657)
Balance, shares at Dec. 31, 2023 17,635,478        
Stock-based compensation expense 2,609,786   2,609,786
Shares sold to investors $ 22 503,066   503,088
Shares sold to investors, shares 223,595        
Stock subscribed by investors $ 6 149,994 (150,000)  
Stock subscribed by investors, shares 66,667        
Net loss     (4,320,827) (4,320,827)
Exercise of stock options $ 17 209,983   $ 210,000
Exercise of stock options, shares 170,000       170,000
Settlement of account payable through issuance of common stock $ 7 149,993   $ 150,000
Settlement of account payable through issuance of common stock, shares 75,000        
Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC $ 30 665,970     666,000
Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC, shares 296,000        
Stock issued to vendor $ 6 124,994     125,000
Stock issued to vendor, shares 55,555        
Balance at Dec. 31, 2024 $ 1,852 14,115,560 (150,000) (15,430,022) (1,462,610)
Balance, shares at Dec. 31, 2024 18,522,295        
Stock-based compensation expense 1,040,594 1,040,594
Collection of stock subscription receivable 150,000 150,000
Shares sold to investors $ 18 397,982 398,000
Shares sold to investors, shares 176,889        
Stock subscribed by investors $ 5 124,995 (125,000)    
Stock subscribed by investors, shares 55,555        
Net loss   (2,428,595) $ (2,428,595)
Exercise of stock options, shares        
Settlement of account payable through issuance of common stock        
Balance at Dec. 31, 2025 $ 1,875 $ 15,679,131 $ (125,000) $ (17,858,617) $ (2,302,611)
Balance, shares at Dec. 31, 2025 18,754,739